To help doctors select the optimal treatment [6], International Neuroblastoma Risk Group (INRG) combines INRGSS information, histologic category, MYCN status, and other factors to classify patients into low-, intermediate- and high-risk groups. The gene discussed is MYCN; the disease is neuroblastoma.